Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Deputy Editor

Having previously worked in the European chemicals industry, Dave has now spent almost a decade with Generics bulletin. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Advertisement
Set Alert for Articles By David Wallace

Latest From David Wallace

Oxytetracycline Prices Double As Hydrocortisone Plunges In UK

July saw UK generic trade price rises peak at a 100% increase for oxytetracycline 250mg tablets, while hydrocortisone 20mg tablets saw their average price plummet by two-thirds, according to the latest figures from WaveData.

United Kingdom Pricing Strategies

Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Regulation United States

Perrigo Remains Committed To Splitting Off Prescription Despite Delay

Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.

Strategy Sales & Earnings

US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Biosimilars Intellectual Property

China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

Deals Strategy

Two Weeks Remain To Enter Industry Awards

Firms now have until 23 August to enter the Global Generics & Biosimilars Awards 2019.

Generic Drugs Biosimilars
See All
Advertisement
UsernamePublicRestriction

Register